Early Data Suggest Nivolumab Has Benefits in RCC

Share this content:

the Cancer Therapy Advisor take:

Nivolumab, which is already being investigated as a potential treatment for non-small cell lung cancer, melanoma, head and neck cancer, glioblastoma, and both Hodgkin and non-Hodgkin lymphoma, has shown success in early trials involving patients with renal cell carcinoma (RCC). As reported by Bristol-Myers Squibb, results from the phase 2 Checkmate -010 trial demonstrated antitumor activity when used as monotherapy in patients with RCC. A second phase1b study—Checkmate -016—indicate that nivolumab was also successful when used in combination with ipilimumab in patients with RCC. Further data will be presented at ASCO 2014.

Early Data Suggest Nivolumab Has Benefits in RCC
Early Data Suggest Nivolumab Has Benefits in RCC
Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. In the Phase 2 CheckMate -010 trial> who received prior anti-angiogenic treatment.
READ FULL ARTICLE From News Medical

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs